A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)
Latest Information Update: 11 Sep 2024
At a glance
- Drugs Selumetinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-1
- Sponsors AstraZeneca
- 11 Sep 2024 This trial has been completed in Hungary.
- 09 May 2024 Planned End Date changed from 29 Dec 2022 to 31 Dec 2024.
- 22 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2022.